RE: Department
of Defense (DoD), Defense Health Program (DHP), Congressionally
Directed Medical Research Programs, Defense Medical Research and
Development Program - Defense Medical Research
Program Announcement
The JPC-8/CRMRP is one of six major DHP core research program
areas within the DHP DHA RDA Directorate and is administered with oversight
from JPC-8, which consists of Department of Defense (DoD) and non-DoD medical
and military technical experts relevant to the program area.
The JPC-8/CRMRP focuses on innovations to reconstruct,
rehabilitate, and provide definitive care for injured Service members. The
ultimate goal is to return the Service members to duty and restore their
quality of life. Innovations developed from JPC-8/CRMRP-supported research
efforts are expected to improve restorative treatments and rehabilitative care
to maximize function for return to duty (RTD) or civilian life. The interest
is in medical technologies (drugs, biologics, and devices) and
treatment/rehabilitation strategies (methods, guidelines, standards, and
information) that will significantly improve the medical care provided to our
wounded Service members within the DoD health care system. Implementation
of these technologies and strategies should improve the rate of RTD of Service
members, the time to RTD, clinical outcome measures, and quality of life, as
well as reduce the hospital stay lengths, clinical workload (patient
encounters, treatments, etc.), and initial and long-term costs associated with
restorative and rehabilitative or acute care.
FY15
Extremity Regeneration Technology/Therapeutic Development Award
Independent
extramural investigators at all academic levels (or equivalent)
|
|
Supports
the translation of promising preclinical findings into products focused on
extremity regeneration.
• The
focus is on bone and soft tissue reconstruction, limb and tissue salvage
technologies, and regenerative medicine technologies for the treatment of
trauma-induced damage.
• Must
specifically address one or both of the FY15 Focus Areas.
•
Research involving human subjects and human anatomical substances is
permitted; however, this award mechanism may not be used to conduct clinical
trials.
The
maximum period of performance is 3 years.
The
maximum allowable funding (total costs) for the entire period of performance
is $2.1 Million.
|
|
A pre-application is
required and must be submitted through the electronic Biomedical Research
Application Portal (eBRAP) at https://eBRAP.org prior
to the pre-application deadline. All applications must conform to the final
Program Announcements and General Application Instructions available for
electronic downloading from the Grants.gov website. The application
package containing the required forms for each award mechanism can also be
found on Grants.gov. A listing of all CDMRP funding opportunities can be
obtained on the Grants.gov website by performing a basic search using CFDA
Number 12.420.
Applications must be
submitted through the federal government’s single-entry portal, Grants.gov. Requests for
email notification of the Program Announcements release may be sent to help@ebrap.org. For more
information about the PRORP or other CDMRP-administered programs, please visit
the CDMRP website (http://cdmrp.army.mil).
Point of
Contact:
CDMRP Help Desk
help@eBrap.org
help@eBrap.org
No comments:
Post a Comment